<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="5" ids="28304">Heparin</z:chebi> and heparinoids have long been proposed for <z:hpo ids='HP_0001297'>stroke</z:hpo> treatment </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigates the effect of enoxaparin (Lovenox, Clexane), a low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi>, on functional outcome (neuroscore) and lesion size in <z:hpo ids='HP_0001297'>stroke</z:hpo> models with reversible and irreversible <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> using middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) in the rat </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> was induced in rats by transient occlusion for 2 hours or by permanent electrocoagulation of the left <z:chebi fb="70" ids="34342">MCA</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-eight hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, neurological deficit was evaluated by scoring sensorimotor functions and ischemic damage was quantified by histological evaluation of lesion volumes </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: After transient MCAO, enoxaparin at 2x1.5 mg/kg IV (2 and 24 hours after insult) significantly reduced lesion size by 30% (P&lt;0.05) and improved neuroscore (P&lt;0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>This significant effect on lesion size and neuroscore was still evident when treatment was started 5 hours after insult </plain></SENT>
<SENT sid="6" pm="."><plain>Administered under the same protocol with a 5 hours delay post permanent MCAO, enoxaparin reduced lesion size by 49% (P&lt;0.05) and improved neuroscore (P&lt;0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: This study indicates that standard nonhemorrhagic doses of enoxaparin reduce ischemic damage with a wide therapeutic window </plain></SENT>
<SENT sid="8" pm="."><plain>In addition to its <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> properties, other properties of enoxaparin could act in synergy to explain its neuroprotective profile in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Thus clinical application of enoxaparin treatment in <z:hpo ids='HP_0001297'>stroke</z:hpo> warrants serious consideration </plain></SENT>
</text></document>